2018 Zytiga Drug Analysis: A Small Molecule Oral Irreversible Inhibitor of the 17 alpha-hydroxylase Enzyme by Johnson & Johnson - ResearchAndMarkets.com

DUBLIN--()--The "Drug Analysis: Zytiga" drug pipelines has been added to ResearchAndMarkets.com's offering.

Zytiga (abiraterone acetate; Johnson & Johnson/AstraZeneca) is a small molecule oral irreversible inhibitor of the 17 alpha-hydroxylase enzyme which catalyzes the hydroxylation of intermediates involved in testosterone synthesis. Prostate cancer cell growth is commonly driven by hormones, and as Zytiga inhibits the rate-limiting enzyme in androgen synthesis, it blocks testosterone production activity in the testes, adrenal glands, and prostate, while preserving adrenal sufficiency.

Market Data

List of Figures

Figure 1: Zytiga for prostate cancer - SWOT analysis

Figure 2: Drug assessment summary of Zytiga for prostate cancer

Figure 3: Drug assessment summary of Zytiga for prostate cancer

Figure 4: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Zytiga drug profile

Table 2: Zytiga Phase III data in prostate cancer

Table 3: Zytiga Phase III trials in prostate cancer

Table 4: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/hkwd8d/2018_zytiga_drug?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Prostate Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Prostate Cancer Drugs